Stoney Bowman
Psychiatric/Mental Health · Durham, NCNPI 1528554219
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.6% of the total across 489 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 25.2% of the total. Reporting peaked in 2022 at $2,973 and has fallen 86.1% since, to $414 in 2025. Among psychiatric/mental health clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 489 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Alkermes, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Supernus Pharmaceuticals, Inc.$483
- Johnson & Johnson$460
- plus $2K from 15 others
What the payments were for
- Speaking & faculty fees$4505%
- Food & beverage$8,34992%
- Education$3143%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 110 | $2,300 |
| Teva Pharmaceuticals USA, Inc. | 113 | $1,813 |
| Alkermes, Inc. | 70 | $1,160 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 74 | $1,090 |
| Supernus Pharmaceuticals, Inc. | 21 | $483 |
| Johnson & Johnson | 18 | $460 |
| Otsuka America Pharmaceutical, Inc. | 16 | $386 |
| AbbVie | 21 | $354 |
| Corium, LLC | 10 | $288 |
| Lundbeck LLC | 9 | $212 |
| Neurocrine Biosciences, Inc. | 9 | $199 |
| E.r. Squibb & Sons, L.L.C. | 4 | $99 |
| Ironshore Pharmaceuticals Inc. | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Almatica Pharma LLC | 2 | $38 |
| Bausch Health US, LLC | 2 | $36 |
| Tris Pharma Inc | 1 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Neos Therapeutics, LP | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,112 in reported general payments places this provider in the 95th percentile of 947 psychiatric/mental health providers in North Carolina.
See all psychiatric/mental health providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 156 | $429,667 |
| SpravatoEsketamine Hcl | 141 | $214,503 |
| Abilify MaintenaAripiprazole | 74 | $198,438 |
| Invega TrinzaPaliperidone Palmitate | 23 | $170,713 |
| AristadaAripiprazole Lauroxil | 22 | $74,229 |
| RexultiBrexpiprazole | 23 | $34,791 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 37 | $29,602 |
| CaplytaLumateperone Tosylate | 17 | $27,519 |
| Lurasidone Hcl | 138 | $22,648 |
| VraylarCariprazine Hcl | 12 | $18,802 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 70 | $10,738 |
| Clozapine | 105 | $8,355 |
| Aripiprazole | 241 | $5,787 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,644 |
| BelsomraSuvorexant | 11 | $4,960 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Spravato, Invega Trinza | $460 | $814,883320 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $386 | $233,22997 claims |
| Alkermes, Inc.Aristada | $1,160 | $74,22922 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,090 | $27,51917 claims |
| AbbVieVraylar | $354 | $18,80212 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $47 | $5,64412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 947 psychiatric/mental health providers in North Carolina.
Other psychiatric/mental health in Durham
- Victoria OblerDurham$10K
- Valerie Idada ParkerDurham$10K
- Desiree MatthewsCharlotte$807K
- Benedetto PalomboCharlotte$671K
- Clarence RunnelsCreedmoor$339K
- Lisa SuddrethGastonia$111K
- April NandigamGreensboro$88K
- Hannah NealeyFuquay Varina$75K
- Jessica StoneRocky Mount$63K
- Deborah GranickRaleigh$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.